NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Forecast & News

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Sorrento Therapeutics.

3 brokers have issued twelve-month price objectives for Sorrento Therapeutics' stock. Their forecasts range from $12.00 to $30.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 876.7% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.

Media coverage about SRNE stock has been trending extremely negative on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a media sentiment score of -4.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Sorrento Therapeutics.

Some companies that are related to Sorrento Therapeutics include Intrexon (XON), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Eloxx Pharmaceuticals (ELOX), Bioanalytical Systems (BASI), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), HedgePath Pharmaceuticals (HPPI), Tenax Therapeutics (TENX), US Stem Cell (USRM), Vitality Biopharma (VBIO) and Protalex (PRTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Novavax (NVAX), Amarin (AMRN), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Cara Therapeutics (CARA), Alibaba Group (BABA) and Exelixis (EXEL).

Sorrento Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.36%), Geode Capital Management LLC (1.02%), Bank of New York Mellon Corp (0.24%), Charles Schwab Investment Management Inc. (0.19%), Alliancebernstein L.P. (0.16%) and Barclays PLC (0.13%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd and George K Ng. View Institutional Ownership Trends for Sorrento Therapeutics.

SRNE stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Bank of America Corp DE, Integrated Wealth Concepts LLC, Bank of New York Mellon Corp and Matrix Asset Advisors Inc. NY. View Insider Buying and Selling for Sorrento Therapeutics.

SRNE stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Goldman Sachs Group Inc., Barclays PLC, Alliancebernstein L.P., California Public Employees Retirement System, Virtu Financial LLC, UBS Group AG and Credit Suisse AG. View Insider Buying and Selling for Sorrento Therapeutics.

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SRNE stock can currently be purchased for approximately $2.15.

Sorrento Therapeutics has a market capitalization of $360.77 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.

The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com/.

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]